Oxcarbazepine-Induced Hyponatremia and the Regulation of Serum Sodium after Replacing Carbamazepine with Oxcarbazepine in Children

Abstract

While severe hyponatremia is reported to be more frequent in adults treated with oxcarbazepine (OXC) than with carbamazepine (CBZ), there is not sufficient data about the incidence of hyponatremia in childhood during treatment with OXC. We evaluated changes in serum electrolyte balance in 75 children with epilepsy before and during treatment with OXC and after replacing carbamazepine (CBZ) therapy with OXC therapy. All patients had normal sodium serum levels at the onset of OXC. During treatment with OXC we found hyponatremia (Na⁺< 135 mmol/l) without clinical symptoms in 26.6 % of the children (n = 20), sodium levels below 125 mmol/l were observed in 2 children (2.6 %). Clinically relevant hyponatremia occurred in one girl only (1.3 %). In a subgroup of 27 children, in whom CBZ was directly replaced with OXC, hyponatremia without symptoms was found in one child under CBZ (3.7 %) and in six children under OXC (22.2 %). Dosage of OXC, serum levels of the active metabolite of OXC, antiepileptic comedication or patients' age and gender were of no predictive value for the development of hyponatremia. Electrolytes should be measured before establishing OXC and if clinically relevant side effects occur.

Oxacarbazepine - Carbamazepine - Side Effect - Children - Hyponatremia - Electrolyte Monitoring

References

• 1 Borusiak P, Korn-Merker E, Holert N, Boenigk H E. Hyponatremia induced by oxcarbazepine in children.  Epilepsy Res. 1998;  30 241-246
• 2 Borusiak P, Korn-Merker E, Holert N, Boenigk H E. Oxcarbazepine in treatment of childhood epilepsy: A survey of 46 children and adolescents.  J Epilepsy. 1998;  11 355-360
• 3 Dam M. Practical aspects of oxcarbazepine treatment.  Epilepsia. 1994;  35 23-25
• 4 Friis M L, Kristensen O, Boas J, Dalby M, Deth S H, Gram L, Mikkelsen M, Pedersen B, Sabes A, Worm-Petersen J, Andersen D, Jensen P K. Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment.  Acta Neurol Scand. 1993;  87 224-227
• 5 Homberg V, Kowalik A, Schulze-Bonhage A. Ad hoc-Umstellung von Carbamazepin auf Oxcarbazepin - Effektivität und Tolerabilität. Eine retrospektive Analyse (Ad hoc change from carbamazepine to oxcarbazepine - effectiveness and tolerance. A retrospective analysis).  Nervenarzt. 2001;  72 918-923
• 6 Isojarvi J I, Huuskonen U E, Pakarinen A J, Vuolteenaho O, Myllyla V V. The regulation of serum sodium after replacing carbamazepine with oxcarbazepine.  Epilepsia. 2001;  42 741-745
• 7 Nielsen O A, Johannessen A C, Bardrum B. Oxcarbazepine-induced hyponatremia, a cross-sectional study.  Epilepsy Res. 1988;  2 269-271
• 8 Schmidt D, Arroyo S, Baulac M, Dam M, Dulac O, Friis M L, Kalviainen R, Kramer G, van Parys J, Pedersen B, Sachdeo R. Recommendations on the clinical use of oxcarbazepine in the treatment of epilepsy: a consensus view.  Acta Neurol Scand. 2001;  104 167-170
• 9 Smith P E. The UK Oxcarbazepine Advisory Board. Clinical recommendations for oxcarbazepine.  Seizure. 2001;  10 87-91
• 10 Steinhoff B J, Stoll K D, Stodieck S RG, Paulus W. Hyponatremic coma under oxcarbazepine therapy.  Epilepsy Res. 1992;  11 67-70
• 11 Tecoma E S. Oxcarbazepine.  Epilepsia. 1999;  40 (Suppl 5) S37-S46
• 12 Thomas L. Labor und Diagnose. Marburg; Die medizinische Verlagsgesellschaft 1992
• 13 Van Amelsfort T, Bakshi R, Devaux C B, Schwabe S. Hyponatremia associated with carbamazepine and oxcarbazepine therapy: a review.  Epilepsia. 1994;  35 181-188